{
    "nct_id": "NCT04123795",
    "official_title": "Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis",
    "inclusion_criteria": "* Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:\n\n  1. Body Surface Area (BSA) affected by psoriasis ≥10 %\n  2. Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4)\n  3. Psoriasis Area and Severity Index (PASI) score is ≥12 or\n  4. PASI score is ≥10 and <12 with at least one of the following:\n\n     * Clinically relevant facial or scalp involvement\n     * Clinically relevant genital involvement\n     * Clinically relevant palm and sole involvement\n     * Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with >50 % to <80 % guttate lesions for ≥3 months, and must meet the same criteria listed above\n* Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Study participant previously participated in this study or has previously been treated with certolizumab pegol (CZP)\n* Study participant has generalized pustular or erythrodermic psoriasis (PSO)\n* Study participant has guttate PSO without plaque PSO\n* Study participant has had a primary failure to an anti-tumor necrosis factor agent\n* Study participant has had prior exposure to >2 biologic therapies\n* Study participant has a history of severe major depression or suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a positive response (\"Yes\") to either Question 4 or Question 5 of the \"Screening/Baseline\" version of the Columbia Suicide Severity Rating Scale (CSSRS) at Screening",
    "miscellaneous_criteria": ""
}